Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESP Block in Robotic Cardiac Surgery
NCT05702151Unknown
- Sponsor
- Hospital Clínic de Barcelona
- Start
- Dec 2022
- Primary completion
- Mar 2024
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Randomised, open-label trial of ropivacaine hydrochloride liposomal suspension injection in postoperative pain (2 arms), sponsored by Hospital Clínic de Barcelona. Primary endpoints: Accumulated opioid dose at 48 hours and Visual Analog Scale at 48 hours. Status: unknown.
02
Drugs
ropivacaine hydrochloride liposomal suspension injection
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT05702151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05702151.